CTRI/2023/08/057127尚未招募3 期
A Multi-Center, Double-blind, Randomized, Placebo-controlled, Parallel-Group, Phase III Clinical Study to Evaluate the Efficacy and Safety of Pilocarpine Hydrochloride Ophthalmic Solution USP 1.25% w/v Versus Placebo Ophthalmic Solution for the Treatment of Presbyopia - Nil
Entod Pharmaceuticals Limited0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Adult male and female subjects, 45 to 55 years of age (both inclusive).
- •2. Subjects with Objective and subjective evidence of Presbyopia.
- •3. Subjects with subjective complaints of poor near vision that impacts the activity of daily living.
- •4. Subjects with photopic, high-contrast corrected distance visual acuity (CDVA) of 20/25 or better bilaterally; mesopic, high-contrast distance-corrected near visual acuity (DCNVA, measured at 40 cm) of 20/40 to 20/100; photopic, near visual acuity correctable to 20/40 or better bilaterally
- •5. Subjects with willingness to wear monofocal correction to achieve photopic, binocular CDVA of 20/32 or better during the study (if required).
- •6. Subjects who are able to understand and give voluntary, written informed consent to participate in this clinical investigation and from whom written consent has been obtained.
- •7. Subjects shall be willing and able to understand and comply with the requirements of the study, administer the study medication as instructed, return for the required treatment period visits, comply with therapy prohibitions, and be able to complete the study.
- •8. Female Subjects, of child-bearing potential practicing an acceptable method of birth control such as sexual abstinence, intrauterine device IUD, birth control pills, a double-barrier method, transdermal, injection or implants, non-hormonal or hormonal, condom plus spermicide, diaphragm plus spermicide, or vaginal spermicidal suppository; for the duration of the study as judged by the investigator(s)/study physician and agree to follow the same should be used during treatment
- •OR Postmenopausal for at least 1 year OR Surgically sterile (bilateral tubal ligation/bilateral oophorectomy/ hysterectomy has been performed on the Subject).
排除标准
- •1. Documented/suspected history of hypersensitivity to the study medications or any of the ingredients of the formulation or cholinergic agonist medications.
- •2. Subjects with History of cataract surgery, phakic intraocular lens surgery, corneal inlay surgery, radial keratotomy, or any other intraocular surgery. However, Subjects with history of Photorefractive keratectomy (PRK) or Laser-assisted in situ keratomileusis (LASIK) with CDVA meeting inclusion criteria will be allowed to enrol.
- •3. Subjects with concurrent use of any topical ophthalmic medications including artificial tears, other than the study intervention during the course of the study.
- •4. Subjects with concurrent use of temporary or permanent punctual plugs or history of punctual cautery in one or both eyes.
- •5. Subjects with current enrolment in an investigational drug or device study or participation in such a study within 30 days of entry into this study.
- •6. Subjects with participation in a blood or plasma donation program within 30 days prior to the study intervention administration.
- •7. Subjects with severe dry eye disease
- •8. Subjects with corneal abnormalities (including Keratoconus, corneal scar, Fuch’s endothelial dystrophy, guttata or edema) in either eye that are likely to interfere the visual acuity.
- •9. Subjects with history of iris trauma, Adie’s tonic pupil, abnormal pupil shape in either eye, or anisocoria >1mm between pupils under mesopic conditions at the screening visit.
- •10. Subjects with all grades of cataract.
- •11. Subjects with diagnosis of Glaucoma or ocular Hypertension.
- •12. Subjects with Bifocal or multifocal spectacles or contact lenses for habitual correction.
- •13. Females who are pregnant, nursing or planning a pregnancy during the study.
- •14. Subjects with history of chronic, recurrent, or current severe inflammatory eye disease (i.e., scleritis, uveitis, herpes keratitis) in either eye.
- •15. Subjects with documented history of ocular trauma = 6 months before the study.
- •16. Subjects with documented history of clinically significant or progressive retinal disease (e.g., retinal degeneration, diabetic retinopathy, retinal detachment) in either eye.
- •17. Subjects with one eye.
- •18. Subjects with severe illness or other condition that would make the patient unsuitable for the study, as per investigator discretion.
- •19. Subjects with active or prior severe, unstable, or uncontrolled cardiovascular, cerebrovascular, hepatic, or renal disease.
- •20. Subjects with use of topical ophthalmic corticosteroid within two weeks prior to baseline visit.
- •21. Subjects with use of intraocular corticosteroid implant at any time prior to baseline visit.
- •22. Subjects with clinically significant laboratory abnormalities at the time of screening.
- •23. Currently taking prohibited concomitant medications(s) listed and inability/unwillingness to discontinue them for the entire study period.
- •24. Subjects who are known seropositive cases of HIV, Hepatitis B or Hepatitis C.
- •25. Subjects who have a recent history or who are currently known to abuse alcohol or drugs.
- •26. Suspected inability or unwillingness to comply with the protocol or other study procedures.
研究者
相似试验
未知
2 期
A Study of Adalimumab for the Induction of Clinical Remission in Japanese Subjects with Crohn's DiseaseCrohn's diseaseJPRN-jRCT2080220357Abbott Japan Co., Ltd.80
进行中（未招募）
不适用
The purpose of this study is to demonstrate the efficacy and safety of adalimumab for the induction of clinical remission in Japanese subjects with Crohn's disease.Crohn's DiseaseEUCTR2014-004560-38-Outside-EU/EEAAbbott Deutschland GmbH & Co. KG80
进行中（未招募）
不适用
A Study of Adalimumab for the Maintenance of Clinical Remission in Japanese Subjects With Crohn's Disease.Crohn's DiseaseEUCTR2014-004531-39-Outside-EU/EEAAbbott Deutschland GmbH & Co. KG80
进行中（未招募）
1 期
A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Two-arm Safety and Efficacy Study of SYN118 as Adjunctive Therapy in Subjects with Parkinson?s DiseaseEUCTR2009-013670-41-FRSynosia Therapeutics AG126
进行中（未招募）
不适用
A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Two-arm Safety and Efficacy Study of SYN118 as Adjunctive Therapy in Subjects with Parkinson?s DiseaseParkinson´s disease inadequately controlled on a stable regimen of anti-Parkinsonian medications.MedDRA version: 12.0Level: LLTClassification code 10013113Term: Disease Parkinson'sEUCTR2009-013670-41-CZSynosia Therapeutics AG126